Summary page of the EQA programme
This page provides the information about the programme in a nutshell. It is as concise as it can be.
The programme is focused on external quality assessment of the PD-L1 staining of 4 carcinoma types (subschemes TNBC, NSCLC, UC and HNSCC).
Complete description you can find in the EQA Plan 2023 (namely page 31).
Short description is available in the PDL1 2023 flyer.
|European Society of Pathology Quality Assurance Foundation|
Barastraat 6, 1070 Brussels, Belgium
|SEKK s.r.o., EHK Division|
Arnošta z Pardubic 2605, 530 02 Pardubice, Czech Republic
The laboratories from all countries are welcome to participate in PDL1 programme.
Very simple guide on how to order the Programmed Death Ligand 1 (PDL1) and Programmed Death Ligand 1 (PDL1) programmes is available here.
The participants are free to order aby combination of the carcinoma types (subschemes).
Each participant examines 1 physical slide and 1 virtual slide for each carcinoma type they ordered.
The table shows complete collection of the samples:
|Samples in the set|
Each slide bears one TMA section.
The columns (A to H) represent individual primary samples (carcinomas) different for each set (thus column A in TNBC slide is a tissue different from the column A in other slides).
There are 3 cores of each primary sample in the physical slide TMA (rows 1 to 3).
Blackened cores (● ●) represent tonsillar tissue (serve as block orientation element and staining quality indicator).
We believe that these examples will give you a good insight.
|Public part of the evaluation|
(EQA round PDL12/22)
|Private part of the evaluation|
(anonymised and shortened examples from the EQA round PDL12/22)
Confirmation of attendance
|Certificate of approval||Result sheet||Histograms|
To view the latest finished EQA round (PDL12/22) please click here.
Last update: 19.11.2022